Addex Therapeutics Ltd (SWX:ADXN)

Market Cap	5.88M
Revenue (ttm)	246.19K
Net Income (ttm)	8.67M
Shares Out	98.35M
EPS (ttm)	0.09
PE Ratio	0.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,651
Average Volume	304,902
Open	0.0592
Previous Close	0.0592
Day's Range	0.0584 - 0.0600
52-Week Range	0.0472 - 0.1095
Beta	1.99
RSI	53.03
Earnings Date	Jun 19, 2025

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN